Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 17/20 | 0.73 |
| ▸ | PGR | P06401 | 14/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449015 | 0.92 | NR3C1 (0.71) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292704 | 0.91 | NR3C1 (0.70) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292952 | 0.91 | NR3C1 (0.70) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL291749 | 0.91 | NR3C1 (0.74) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292559 | 0.90 | NR3C1 (0.73) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL291385 | 0.90 | NR3C1 (0.78) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL292282 | 0.90 | NR3C1 (0.72) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL291411 | 0.90 | NR3C1 (0.72) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL1634790 | 0.88 | NR3C1 (0.81) | NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL3805972 | 0.87 | NR3C1 (0.64) | NR3C1NR3C2PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
| EP-2049112-B1 | TREATING INFECTIONS AND SEQUELAE THEREOF WITH COMBINED DISSOCIATED GLUCOCORTICOID RECEPTOR AGONISTS AND ANTI-INFECTIVE AGENTS | BAUSCH & LOMB (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20110281882-A1 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain | 1261229 B.C. LTD. (CA) | 2011-11-17 | — | — | US | disclosed |
| EP-2051710-B1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2364707-A2 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110104159-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH+LOMB OPS B.V. (NL) | 2011-05-05 | — | — | US | disclosed |
| US-20110105559-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-05-05 | — | — | US | disclosed |
| EP-2061444-B1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | BAUSCH & LOMB (US) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281882-A1 | Compositions and Methods for Treating, Controlling, Reducing, or Ameliorating Inflammatory Pain | PTGIR, MC2R, NR3C1 | NR3C1 3/4885NR3C2 18/4885PGR 220/4885 |
| US-20110104159-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, AMELIORATING, OR PREVENTING ALLERGY | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885NR3C2 87/4885PGR 123/4885 |
| US-20110105559-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885NR3C2 87/4885PGR 123/4885 |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885NR3C2 11/4885PGR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.